Milestone’s etripamil nasal spray enters Phase III trial for atrial fibrillation
Milestone Pharmaceuticals has commenced a pivotal Phase III trial of its etripamil nasal spray aimed at treating atrial fibrillation with…
All articles by Srivani Venna
Srivani Venna
-
-
Orum to begin Phase I trial of ORM-1153 after FDA clearance
The US Food and Drug Administration (FDA) has approved Orum Therapeutics' investigational new drug (IND) application for ORM-1153, a new…
-
DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 study
PepGen has announced that an independent Data and Safety Monitoring Board (DSMB) has approved the progression to the highest dosage…
-
First patient dosed with DISP-10 in Dispatch Bio’s cancer trial
Dispatch Bio has dosed the first participant in a Phase I clinical trial aimed at evaluating the efficacy and safety…
-
J&J’s Mark Graham on advancing nipocalimab as treatment for SLE
J&J EMEA Immunology therapeutic area head Mark Graham tells Srivani Venna that based on positive data from the Phase II…
-
GSK announces positive outcomes from Phase I BEHOLD-1 trial of Mo-Rez
GSK has shared encouraging data from its Phase I BEHOLD-1 clinical trial of mocertatug rezetecan (Mo-Rez), an antibody-drug conjugate targeting…
-
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
BioNTech and DualityBio reported encouraging data from a Phase II cohort of their global clinical study evaluating the efficacy of…
-
Sirius and CRISPR dose first subject in trial of thromboembolic disorders therapy
Sirius Therapeutics and CRISPR Therapeutics have dosed the first patient in a Phase II trial of SRSD107 for thromboembolic disorders…
-
WCG unveils clinical trial training solution to cut deviations
WCG has introduced Total Training, a clinical trial solution designed to reduce protocol deviations and enhance site readiness, engagement, and…
-
FDA approves Coya Therapeutics’ trial of COYA 302 for ALS
Coya Therapeutics has announced the acceptance by the US Food and Drug Administration (FDA) of its investigational new drug (IND) application…